You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.
The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
The company is marketing the panel, which runs on NanoString Technologies' nCounter System, to chemical and cosmetics firms as a replacement for animal models.
Data for hundreds of thousands of participants led to 20 new risk loci for allergic rhinitis, which were further examined by functional annotation and fine mapping.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The lab will launch a carrier screening test this year, and plans to bring infectious disease, allergy, cognitive health, and toxicology tests as well.
With RNA sequencing on blood samples taken before, during, and after peanut exposure, investigators searched for acute allergy-related genes and cell types.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.